Table 3. Multivariate odds ratio of breast cancer associated with previous fever frequency stratified by clinicopathological characteristics.
| Characteristics | Fever frequency | IFN-γ rs2069705 | ||||||
| Frequency (time/year) | Casesn (%) | Controlsn (%) | OR (95%CI)a | Genotype | Cases n (%) | Controls n (%) | OR (95%CI)a | |
| Menopause | ||||||||
| Premenopausal | <1 | 330 (76.6) | 268 (73.8) | 1.00 (reference) | CC | 242 (52.7) | 207 (52.5) | 1.00 (reference) |
| ≥1 | 101 (23.4) | 95 (26.2) | 0.82 (0.58–1.15) | CT/TT | 217 (47.3) | 187 (47.5) | 0.96 (0.73–1.28) | |
| Postmenopausal | <1 | 224 (75.4) | 278 (69.8) | 1.00 (reference) | CC | 156 (47.9) | 219 (52.8) | 1.00 (reference) |
| ≥1 | 73 (24.6) | 120 (30.2) | 0.71 (0.50–1.03) | CT/TT | 170 (52.1) | 196 (47.2) | 1.18 (0.86–1.61) | |
| P a for interaction (multiplicative/additive) | 0.685/0.596 | 0.491/0.750 | ||||||
| BMI | ||||||||
| <24 | <1 | 341 (73.5) | 349 (70.9) | 1.00 (reference) | CC | 261 (52.2) | 277 (53.0) | 1.00 (reference) |
| ≥1 | 123 (26.5) | 143 (29.1) | 0.88 (0.65–1.18) | CT/TT | 239 (47.8) | 246 (47.0) | 0.97 (0.75–1.26) | |
| ≥24 | <1 | 198 (81.1) | 180 (72.6) | 1.00 (reference) | CC | 123 (46.4) | 135 (51.7) | 1.00 (reference) |
| ≥1 | 46 (18.9) | 68 (27.4) | 0.53 (0.33–0.84) | CT/TT | 142 (53.6) | 126 (48.3) | 1.24 (0.86–1.78) | |
| P a for interaction (multiplicative/additive) | 0.099/0.057 | 0.293/0.148 | ||||||
| Clinical stage | ||||||||
| Localized | <1 | 306 (75.2) | 560 (72.1) | 1.00 (reference) | CC | 211 (47.7) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 101 (24.8) | 217 (27.9) | 0.83 (0.62–1.11) | CT/TT | 231 (52.3) | 398 (47.4) | 1.18 (0.93–1.49) | |
| Regional/distant | <1 | 207 (76.7) | 560 (72.1) | 1.00 (reference) | CC | 158 (52.7) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 63 (23.3) | 217 (27.9) | 0.75 (0.53–1.05) | CT/TT | 142 (47.3) | 398 (47.4) | 0.99 (0.75–1.32) | |
| P a for heterogeneity test | 0.469 | 0.184 | ||||||
| ER | ||||||||
| Positive | <1 | 367 (75.1) | 560 (72.1) | 1.00 (reference) | CC | 273 (51.0) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 122 (24.9) | 217 (27.9) | 0.83 (0.63–1.08) | CT/TT | 262 (49.0) | 398 (47.4) | 1.05 (0.84–1.32) | |
| Negative | <1 | 150 (79.4) | 560 (72.1) | 1.00 (reference) | CC | 107 (50.2) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 39 (20.6) | 217 (27.9) | 0.67 (0.45–1.00) | CT/TT | 106 (49.8) | 398 (47.4) | 1.08 (0.79–1.48) | |
| P a for heterogeneity test | 0.235 | 0.911 | ||||||
| PR | ||||||||
| Positive | <1 | 317 (74.8) | 560 (72.1) | 1.00 (reference) | CC | 247 (52.2) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 107 (25.2) | 217 (27.9) | 0.86 (0.65–1.14) | CT/TT | 226 (47.8) | 398 (47.4) | 1.01 (0.80–1.28) | |
| Negative | <1 | 199 (78.7) | 560 (72.1) | 1.00 (reference) | CC | 133 (48.5) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 54 (21.3) | 217 (27.9) | 0.66 (0.46–0.94) | CT/TT | 141 (51.5) | 398 (47.4) | 1.15 (0.86–1.53) | |
| P a for heterogeneity test | 0.123 | 0.459 | ||||||
| HER2 | ||||||||
| Positive/equivocal | <1 | 153 (75.7) | 560 (72.1) | 1.00 (reference) | CC | 115 (50.2) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 49 (24.3) | 217 (27.9) | 0.82 (0.56–1.19) | CT/TT | 114 (49.8) | 398 (47.4) | 1.09 (0.80–1.48) | |
| Negative | <1 | 354 (76.5) | 560 (72.1) | 1.00 (reference) | CC | 258 (51.3) | 442 (52.6) | 1.00 (reference) |
| ≥1 | 109 (23.5) | 217 (27.9) | 0.78 (0.59–1.03) | CT/TT | 245 (48.7) | 398 (47.4) | 1.03 (0.82–1.30) | |
| P a for heterogeneity test | 0.969 | 0.682 | ||||||
a
Adjusted for age, BMI, age at menarche, marital status, education, parity, menopausal status, and family history of breast cancer (excluded the stratified factor in each stratum).
Values in bold indicate statistical significance.